G

Genpharmasec Ltd
BSE:531592

Watchlist Manager
Genpharmasec Ltd
BSE:531592
Watchlist
Price: 2.8 INR -2.78%
Market Cap: 1.6B INR
Have any thoughts about
Genpharmasec Ltd?
Write Note

Intrinsic Value

531592 price has not been updated for more than 2 years. This may indicate that the stock has been delisted.
531592 doesn't have a meaningful market cap.

The intrinsic value of one GENPHARMA stock under the Base Case scenario is 0.92 INR. Compared to the current market price of 2.8 INR, Genpharmasec Ltd is Overvalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GENPHARMA Intrinsic Value
0.92 INR
Overvaluation 67%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Genpharmasec Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GENPHARMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GENPHARMA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Trading Companies & Distributors Industry

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Genpharmasec Ltd

Provide an overview of the primary business activities
of Genpharmasec Ltd.

What unique competitive advantages
does Genpharmasec Ltd hold over its rivals?

What risks and challenges
does Genpharmasec Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genpharmasec Ltd.

Provide P/S
for Genpharmasec Ltd.

Provide P/E
for Genpharmasec Ltd.

Provide P/OCF
for Genpharmasec Ltd.

Provide P/FCFE
for Genpharmasec Ltd.

Provide P/B
for Genpharmasec Ltd.

Provide EV/S
for Genpharmasec Ltd.

Provide EV/GP
for Genpharmasec Ltd.

Provide EV/EBITDA
for Genpharmasec Ltd.

Provide EV/EBIT
for Genpharmasec Ltd.

Provide EV/OCF
for Genpharmasec Ltd.

Provide EV/FCFF
for Genpharmasec Ltd.

Provide EV/IC
for Genpharmasec Ltd.

Compare the intrinsic valuations
of Genpharmasec Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genpharmasec Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genpharmasec Ltd compared to its peers.

Compare the P/E ratios
of Genpharmasec Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Genpharmasec Ltd with its peers.

Analyze the financial leverage
of Genpharmasec Ltd compared to its main competitors.

Show all profitability ratios
for Genpharmasec Ltd.

Provide ROE
for Genpharmasec Ltd.

Provide ROA
for Genpharmasec Ltd.

Provide ROIC
for Genpharmasec Ltd.

Provide ROCE
for Genpharmasec Ltd.

Provide Gross Margin
for Genpharmasec Ltd.

Provide Operating Margin
for Genpharmasec Ltd.

Provide Net Margin
for Genpharmasec Ltd.

Provide FCF Margin
for Genpharmasec Ltd.

Show all solvency ratios
for Genpharmasec Ltd.

Provide D/E Ratio
for Genpharmasec Ltd.

Provide D/A Ratio
for Genpharmasec Ltd.

Provide Interest Coverage Ratio
for Genpharmasec Ltd.

Provide Altman Z-Score Ratio
for Genpharmasec Ltd.

Provide Quick Ratio
for Genpharmasec Ltd.

Provide Current Ratio
for Genpharmasec Ltd.

Provide Cash Ratio
for Genpharmasec Ltd.

What is the historical Revenue growth
over the last 5 years for Genpharmasec Ltd?

What is the historical Net Income growth
over the last 5 years for Genpharmasec Ltd?

What is the current Free Cash Flow
of Genpharmasec Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Genpharmasec Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Genpharmasec Ltd

Current Assets 409.7m
Cash & Short-Term Investments 202.6m
Receivables 115.3m
Other Current Assets 91.8m
Non-Current Assets 301.5m
Long-Term Investments 176.4m
PP&E 8.4m
Other Non-Current Assets 116.7m
Current Liabilities 27m
Accounts Payable 23.8m
Other Current Liabilities 3.2m
Non-Current Liabilities 40.3m
Long-Term Debt 32.1m
Other Non-Current Liabilities 8.2m
Efficiency

Earnings Waterfall
Genpharmasec Ltd

Revenue
296.4m INR
Cost of Revenue
-239.6m INR
Gross Profit
56.8m INR
Operating Expenses
-56.7m INR
Operating Income
100.8k INR
Other Expenses
1.2m INR
Net Income
1.3m INR

Free Cash Flow Analysis
Genpharmasec Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GENPHARMA Profitability Score
Profitability Due Diligence

Genpharmasec Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Positive Gross Profit
Positive 3-Years Revenue Growth
Declining ROE
39/100
Profitability
Score

Genpharmasec Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

GENPHARMA Solvency Score
Solvency Due Diligence

Genpharmasec Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Genpharmasec Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GENPHARMA Price Targets Summary
Genpharmasec Ltd

There are no price targets for GENPHARMA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GENPHARMA?

Click here to dive deeper.

Dividends

Genpharmasec Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for GENPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Genpharmasec Ltd

Country

India

Industry

Trading Companies & Distributors

Market Cap

1.5B INR

Dividend Yield

0%

Description

Genpharmasec Ltd. engages in manufacturing and trading in Organic and Inorganic Chemicals, Dyes and Pigments Its products include potassium hydroxide and caustic soda. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of diagnostic equipment, pharmaceutical, medicinal, and medicated preparations, patent medicines, drugs, herbs, and in pharmaceutical, medicinal, and proprietary and industrial preparations, compounds and articles of kinds, chemists, druggists, and chemical manufacturers.

Contact

MAHARASHTRA
Mumbai
Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd.,, Akurli Road, Kandivali (East),
+918655550242
www.genpharmasec.com

IPO

1996-02-05

Employees

2

Officers

See Also

Discover More
What is the Intrinsic Value of one GENPHARMA stock?

The intrinsic value of one GENPHARMA stock under the Base Case scenario is 0.92 INR.

Is GENPHARMA stock undervalued or overvalued?

Compared to the current market price of 2.8 INR, Genpharmasec Ltd is Overvalued by 67%.

Back to Top